Abstract
Microemulsion formulation of repaglinide, a BCS class II hypoglycemic agent with limited oral bioavailability, was developed considering its solubility in various oils, surfactants, and cosurfactants. The pseudo-ternary phase diagrams for microemulsion regions were constructed by water titration method at K m 1:1 and characterized for optical birefringence, percentage transmittance, pH, refractive index, globule size, zeta potential, viscosity, drug content, and thermodynamic stability. To enhance the drug permeation and residence time, the optimized microemulsions having mean globule size of 36.15 ± 9.89 nm was gelled with xanthan gum. The developed microemulsion-based gel was characterized for globule size, zeta potential, pH, and drug content. All evaluation parameters upon gelling were found to be satisfactory. Ex vivo permeability study across rat skin demonstrated higher steady-state flux (P < 0.05) for microemulsion of repaglinide in comparison to the repaglinide microemulsion gel. At the end of 24 h, the cumulative drug permeation from microemulsion and microemulsion gel was found to be 229.19 ± 24.34 and 180.84 ± 17.40 μg/cm2, respectively. The microemulsion formulation showed 12.30-fold increase in flux as compared to drug suspension with highest enhancement ratio (E r ) of 12.36. Whereas microemulsion gel exhibited 10.97-fold increase in flux (with highest E r , 11.78) as compared to repaglinide (RPG) suspension. In vivo efficacy study was performed in normal Sprague-Dawley rats by using oral glucose tolerance test. Results of RPG transdermal microemulsion gel demonstrated remarkable advantage over orally administered RPG by reducing the glucose level in controlled manner. Hence, it could be a new, alternative dosage form for effective therapy of type 2 diabetes mellitus.
Similar content being viewed by others
References
Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. Insulin, oral hypoglycemic agents and the pharmacology of endocrine pancreas. Goodman Gilman’s Pharmacol Basis Ther. 2005;11:1685–735.
Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125(3):217–30.
Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc. 2009;49(1):S3–9.
Guay DRP. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy. 1998;18(6):1195–204.
Aggarwal N, Goindi S, Khurana R. Formulation, characterization and evaluation of an optimized microemulsion formulation of griseofulvin for topical application. Colloids Surf B Biointerfaces. 2013;105:158–66.
Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interf Sci. 2006;123:369–85.
Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterization and transdermal drug delivery potential of microemulsion systems. J Control Release. 2000;69(3):421–33.
Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. Int J Pharm. 2001;228(1–2):161–70.
Lee PJ, Langer R, Shastri VP. Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs. Pharm Res. 2003;20(2):264–9.
Yue Y, Li S, Mo F, Zhong D. Investigation of microemulsion system for transdermal delivery of meloxicam. Int J Pharm. 2006;321(1–2):117–23.
Wan T, Xu T, Pan J, Qin M, Pan W, Zhang G, et al. Microemulsion based gel for topical dermal delivery of pseudolaric acid B: in vitro and in vivo evaluation. Int J Pharm. 2015;493(1–2):111–20.
Zhao L, Wang Y, Zhai Y, Wang Z, Liu J, Zhai G. Ropivacaine loaded microemulsion and microemulsion-based gel for transdermal delivery: preparation, optimization, and evaluation. Int J Pharm. 2014;477:47–56.
Baka E, Comer JEA, Takács-Novák K. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J Pharm Biomed Anal. 2008;46(2):335–41.
Date AA, Nagarsenker MS. Design and evaluation of microemulsions for improved parenteral delivery of propofol. AAPS PharmSciTech. 2008;9(1):138–45.
Von Corswant C, Engström S, Söderman O. Microemulsions based on soybean phosphatidylcholine and triglycerides. Phase behavior and microstructure. Langmuir. 1997;13(19):5061–70.
Bali V, Ali M, Ali J. Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro; pharmacodynamic; pharmacokinetic and stability assessment. Int J Pharm. 2010;403(1–2):46–56.
Aravindaram AS, Raghu Nandan VS, Gowda DV, Khan MS. Development and evaluation of ketoprofen loaded biopolymer based transdermal film. Pharm Lett. 2011;3(3):233–44.
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–61.
Malcolmson C, Sidhu A, Satra C, Kantaria S, Lawrence MJ. Effect of oil on the level of solubilization of testosterone propionate into nonionic oil-in-water microemulsions. J Pharm Sci. 1998;87(1):109–16.
Warisnoicharoen W, Lansley AB, Lawrence MJ. Nonionic oil-in-water microemulsions: effect of oil type on phase behavior. Int J Pharm. 2000;198(1):7–27.
Kawakami K, Yoshikawa T, Moroto Y, Kanaoka E, Takahashi K, Nishihara Y, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs I. Prescription design. J Control Release. 2002;81(1–2):75–82.
Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci. 2000;11:S93–8.
Elnaggar YSR, El-Massik MA, Abdallah OY. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int J Pharm. 2009;380(1–2):133–41.
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45(1):89–121.
Patel MR, Patel RB, Parikh JR, Solanki AB, Patel BG. Effect of formulation components on the in vitro permeation of microemulsion drug delivery system of fluconazole. AAPS PharmSciTech. 2009;10(3):917–23.
Kale NJ, Allen LV. Studies on microemulsions using Brij 96 as surfactant and glycerin, ethylene glycol and propylene glycol as cosurfactants. Int J Pharm. 1989;57(2):87–93.
Sharma G, Wilson K, van der Walle CF, Sattar N, Petrie JR, Kumar MNV. Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur J Pharm Biopharm. 2010;76(2):159–69.
Ellaithy HM, El-Shaboury KMF. The development of cutinalipogels and gel microemulsion for topical administration of fluconazole. AAPS PharmSciTech. 2002;3(4):77–85.
Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A. Microemulsions for topical delivery of estradiol. Int J Pharm. 2003;254(2):99–107.
Tsai YH, Fu LT, Huang CT, Chang JS, Huang YB, Wu PC. Formulation optimization of estradiol microemulsion using response surface methodology. J Pharm Sci. 2011;100(10):4383–9.
Acknowledgements
Authors are thankful to the University of Mumbai for partially funding the present work. Authors acknowledge Dr. Reddy’s Laboratory, Hyderabad, for providing the gift sample of repaglinide. Authors also wish to extend their thanks to Gattefosse–India Pvt. Ltd.; BASF, Germany; Stepan Company, USA; and Signet Chemicals, India, for providing the gift samples of various excipients.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shinde, U.A., Modani, S.H. & Singh, K.H. Design and Development of Repaglinide Microemulsion Gel for Transdermal Delivery. AAPS PharmSciTech 19, 315–325 (2018). https://doi.org/10.1208/s12249-017-0811-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-017-0811-4